AAAAAA

   
Results: 1-7 |
Results: 7
CONFIRMATORY INTERLEUKIN-1 RECEPTOR ANTAGONIST TRIAL IN SEVERE SEPSIS- A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL
Authors: OPAL SM FISHER CJ DHAINAUT JFA VINCENT JL BRASE R LOWRY SF SADOFF JC SLOTMAN GJ LEVY H BALK RA SHELLY MP PRIBBLE JP LABRECQUE JF LOOKABAUGH J DONOVAN H DUBIN H BAUGHMAN R NORMAN J DEMARIA E MATZEL K ABRAHAM E SENEFF M BARBER A BRAYMAN K CERRA F CHALFIN D CHAZEN G CHRISTOU N COONEY R CORBIN R DREW R EMMANUEL G PINES B ERON L FLETCHER R FOULKE G GALLAGHER T GERVICH D GROSSMAN J HALPERN N HANNA C JOHNSON S KUBAK B LODATO R LOVETT M MARSHALL J METZLER M NELSON L FREELAND M OROPELLO J PAZ H RACKOW E RIKER R RISSING P SCHEIN R SCHELD M SCHUSTER D SIBBALD W SILVERMAN H SOMERMEYER M STRANGE C SUMMER W TOPIEL M WHITE J ALESTIG K ANDERSEN PK ANDERSSON J BENNETT D BERG S BLEICHNER G BRUNET F CARLET J DEJONG MJ DREXLER H GARRARD C HESLET L KLOSS T PAUL W REINHART K RENAUD B RITZ R ROMME JH SCHMITZ JE STOCKENHUBER F SUTER P TENAILLON A VAGT A VANDERMEER WM VANDEVENTER S VANLEEUWEN PAM VERHOEF J WEBSTER N WINTER RJ WOLFF M STILES DM DEVOS A CROFT C FAZIO J THOMPSON R WIEDEMANN H ELLISON RT CHINCHILLI VM YARBOROUGH M
Citation: Sm. Opal et al., CONFIRMATORY INTERLEUKIN-1 RECEPTOR ANTAGONIST TRIAL IN SEVERE SEPSIS- A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL, Critical care medicine, 25(7), 1997, pp. 1115-1124
USE OF PREDICTED RISK OF MORTALITY TO EVALUATE THE EFFICACY OF ANTICYTOKINE THERAPY IN SEPSIS
Authors: KNAUS WA HARRELL FE LABRECQUE JF WAGNER DP PRIBBLE JP DRAPER EA FISHER CJ SOLL L ASTIZ M RACKOW EC CARPATI C BALK RA FRIEDMAN B MURE AJ SHAPIRO E MELHOM L SHAPIRO MJ TAYLOR R KEEGAN M OBRIEN J GREENMAN RL SCHEIN R PENA M WASSERLOUF M IBERTI TJ OROPELLO J BENJAMIN E DELGUIDICE R EMMANUEL G LIE T ANDERSON L MARSHALL J DEMAJO W ROTSTEIN O FOSTER D ABRAHAM E MIDDLETON H PERRY C LEVY H FRY DE SIMPSON SQ CROWELL RE NEIDHART M STEVENS D COFFMAN T NARASIMHAN N MERRICK DK BERQUIST W MATZEL K HUEBLER M FOULKE G ALBERTSON T WALBY W ALLEN R BAUGHMAN R HASSELGREN PO FINK MP FAVORITO F THOMAS BT CORBIN R SHELLHORSE GY FRAZIER A WHITE S GARRARD C ACOURT C GERVICH D BRASE R BAGDAHN A COONEY R SMITH JS VINCENT JL FRIEDMAN G BERLOT G FLETCHER JR WILLIAMS MD WRIGHT TF JOHNSON S FEILD C WOLF K MACINTYRE N DUBIN H DURKIN M STAUBACH KH FEIN AM SCHULMAN DB NIEDERMAN MS CHALFIN DB VANLEEUVEN PAM BANDER J IMM A BERNARD G NELSON L STROUD M SAFCSAK K CERRA F RINDAL J MANN H HALPERN N ALICEA M SIBBALD WJ MARTIN CM RUTLEDGE FS PETTI K RUSSELL J KRUGER R DRUMMOND A FISHER CS LANGE P SELFERT T DUROCHER A TENAILLON A BOITEAU R LHERM T LOWRY S COYLE SM BARIE PS DEMARIA E REINES HD SNYDMAN D SCHWAITZBERG S NASRAWAY S GRINDLINGER J SUMMER W DEBOISBLANC B WAHL M ALESTIG K GROSSMAN J MAKI D PAZ HL WEINER M BIHARI D BLEICHNER G DAHN M HALL J WENZEL RP GROSSERODE M COSTIGAN M MILESKI W WEIGELT J YESTON N IRIZARRY C ROSS J ROBBINS J SHELLY MP NIGHTINGALE P OWEN K SANDSTEDT S BERG S SIMON G SENEFF M CONRY K ZIMMERMAN JL DELLINGER RP JOHNSTON R ALLEE P GRANDE PO MYHRE E DHAINAUT JF HAMY I MIRA JP HARMON J WHITE J MCKIE L SILVERMAN H TUMA P BENNETT D LAURELL MH JACOBS S ASH S OPAL SM SLOTMAN GJ IBERTI TJ SADOFF JC STILES DM THOMPSON B PRIOR MJ KNATTERUD G TERRIN M KUFERA J WILKENS P RA K MONROE L SPRUNG C HAMILTON CM MATTHAY R MCCABE W TONASCIA J WIEDMAN H WITTES J THOMPSON BW LABRECQUE JF CATALANO MA CAMPION GV CROFT CR LUSTICK R LOOKABAUGH J GORDON GS NOE L BLOEDOW D SMITH CG BRANNON D KUSH R NG D MOORE E BAZEMORE K GALVAN M WAGNER D HARRELL F STABLEIN D
Citation: Wa. Knaus et al., USE OF PREDICTED RISK OF MORTALITY TO EVALUATE THE EFFICACY OF ANTICYTOKINE THERAPY IN SEPSIS, Critical care medicine, 24(1), 1996, pp. 46-56
INTERLEUKIN-1 CONTRIBUTES TO INCREASED CONCENTRATIONS OF SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR-TYPE-I IN SEPSIS
Authors: VANDERPOLL T FISCHER E COYLE SM VANZEE KJ PRIBBLE JP STILES DM BARIE PS BUURMAN WA MOLDAWER LL LOWRY SF
Citation: T. Vanderpoll et al., INTERLEUKIN-1 CONTRIBUTES TO INCREASED CONCENTRATIONS OF SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR-TYPE-I IN SEPSIS, The Journal of infectious diseases, 172(2), 1995, pp. 577-580
INFLUENCE OF IL-1 RECEPTOR BLOCKADE ON THE HUMAN RESPONSE TO ENDOTOXEMIA
Authors: VANZEE KJ COYLE SM CALVANO SE OLDENBURG HSA STILES DM PRIBBLE J CATALANO M MOLDAWER LL LOWRY SF
Citation: Kj. Vanzee et al., INFLUENCE OF IL-1 RECEPTOR BLOCKADE ON THE HUMAN RESPONSE TO ENDOTOXEMIA, The Journal of immunology, 154(3), 1995, pp. 1499-1507
INTERLEUKIN-1 RECEPTOR BLOCKADE DOES NOT AFFECT ENDOTOXIN-INDUCED CHANGES IN PLASMA THYROID-HORMONE AND THYROTROPIN CONCENTRATIONS IN MAN
Authors: VANDERPOLL T VANZEE KJ ENDERT E COYLE SM STILES DM PRIBBLE JP CATALANO MA MOLDAWER LL LOWRY SF
Citation: T. Vanderpoll et al., INTERLEUKIN-1 RECEPTOR BLOCKADE DOES NOT AFFECT ENDOTOXIN-INDUCED CHANGES IN PLASMA THYROID-HORMONE AND THYROTROPIN CONCENTRATIONS IN MAN, The Journal of clinical endocrinology and metabolism, 80(4), 1995, pp. 1341-1346
RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Authors: FISHER CJ DHAINAUT JFA OPAL SM PRIBBLE JP BALK RA SLOTMAN GJ IBERTI TJ RACKOW EC SHAPIRO MJ GREENMAN RL REINES HD SHELLY MP THOMPSON BW LABRECQUE JF CATALANO MA KNAUS WA SADOFF JC ASTIZ M CARPATI C BONE RC FREIDMAN B MURE AJ BRATHWAITE C SHAPIRO E MELHORN L TAYLOR R KEEGAN M OBRIEN J SCHEIN R PENA M WASSERLOUF M OROPELLO J BENJAMIN E DELGUIDICE R EMMANUEL G LIE T ANDERSON L MARSHALL J DEMAJO W ROTSTEIN O FOSTER D ABRAHAM E MIDDLETON H PERRY C LEVY H FRY DE SIMPSON SQ CROWELL RE NEIDHART M STEVENS D COFFMAN T NARASIMHAM N MERRICK DK BERGQUIST W MATZEL KE HUEBLER M FOULKE GE ALBERTSON TE WALBY WF ALLEN RP BAUGHMAN R HASSELGREN PO FINK MP FAVORITO F THOMPSON BT CORBIN R SHELLHORSE GY FRAZIER A WHITE S GARRARD C ACOURT C STORER S GERVICH DH FOSHE D BRASE R BAGDAHN A COONEY R SMITH JS MARTIN LF VINCENT JL FRIEDMAN G BERLOT G FLETCHER JR WILLIAMS MD WRIGHT TF JOHNSON S FEILD C WOLF K MACINTYRE N DUBIN HG DURKIN MR DUBIN PK STAUBACH KH FEIN AM SCHULMAN DB NIEDERMAN MS CHALFIN DB VANLEEUWEN PAM BOERMEESTER MA SCHNEIDER AJ BANDER J IMM A BERNARD G NELSON L STROUD M SAFCSAK K CERRA F RINDAL J MANN H HALPERN N SILVERSTEIN J ALICEA M SIBBALD WJ MARTIN CM RUTLEDGE FS PETTI K RUSSELL JA KRUGER R DRUMMOND A LANGE P SEIFERT T DUROCHER A TENAILLON A BOITEAU R LHERM T LOWRY SF COYLE SM BARIE PS DEMARIA E SNYDMAN DR SCHWAITZBERG SD NASRAWAY SA GRINDLINGER J SUMMER W DEBOISBLANC B WAHL M ALESTIG K GROSSMAN J MAKI D PAZ HL WEINER M BIHARI D CAMPBELL D BLEICHNER G DAHN MS LANGE MPA HALL J POHLMAN A WENZEL RP GROSSERODE M COSTIGAN M MILESKI W WEIGELT J YESTON N IRIZARRY C ROSS J ROBBINS J NIGHTINGALE P OWEN K SANDSTEDT S BERG S SIMON GL SENEFF MG CONRY KM ZIMMERMAN JL DELLINGER RP JOHNSTON R ALLEE P GRANDE PO MYHRE E DHAINAUT JF HAMY I MIRA JP HARMON J WHITE J MCKIE L SILVERMAN H TUMA P BENNETT D PORTER JC LAURELL MH JACOBS S ASH S STILES DM PRIOR MJ KNATTERUD G TERRIN M KUFERA J WILKENS P RA K MONROE L SPRUNG C HAMILTON CM MATTHAY R MCCABE W TONASCIA J WIEDEMAN H WITTES J CAMPION GV CROFT CR LUSTICK R LOOKABAUGH J GORDON GS NOE L BLOEDOW D SMITH CG BRANNON D KUSH R NG D MOORE E BAZEMORE K GALVAN M WAGNER D HARRELL F STABLEIN D
Citation: Cj. Fisher et al., RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, JAMA, the journal of the American Medical Association, 271(23), 1994, pp. 1836-1843
HEMATOLOGIC AND IMMUNOMODULATORY EFFECTS OF AN INTERLEUKIN-1 RECEPTORANTAGONIST COINFUSION DURING LOW-DOSE ENDOTOXEMIA IN HEALTHY HUMANS
Authors: GRANOWITZ EV PORAT R MIER JW ORENCOLE SF CALLAHAN MV CANNON JG LYNCH EA YE K POUTSIAKA DD VANNIER E SHAPIRO L PRIBBLE JP STILES DM CATALANO MA WOLFF SM DINARELLO CA
Citation: Ev. Granowitz et al., HEMATOLOGIC AND IMMUNOMODULATORY EFFECTS OF AN INTERLEUKIN-1 RECEPTORANTAGONIST COINFUSION DURING LOW-DOSE ENDOTOXEMIA IN HEALTHY HUMANS, Blood, 82(10), 1993, pp. 2985-2990
Risultati: 1-7 |